Cagrilintide Reference Guide: Amylin Analog for Metabolic Research
Published 2026-06-09 · 7 min read
Cagrilintide is a long-acting synthetic analog of amylin, a 37-residue peptide co-secreted with insulin by pancreatic β-cells. In metabolic research, amylin receptor agonists are studied alongside GLP-1 receptor agonists for their parallel — but mechanistically distinct — effects on satiety signaling, gastric emptying, and body weight regulation.
Cagrilintide is most often encountered in research as the amylin-arm of CagriSema, an experimental combination with semaglutide that investigates additive effects of amylin and GLP-1 receptor pathways on metabolic endpoints.
At a glance
| Compound class | Long-acting amylin receptor agonist (analog) |
| Parent peptide | Human amylin (IAPP, 37-residue peptide) |
| Modification | Lipidation for albumin binding, residue substitutions for stability |
| Receptor target | Amylin receptor (calcitonin receptor + RAMP1/2/3) |
| Half-life (literature) | ~7 days (designed for once-weekly dosing in research models) |
| Typical research vial size | 5 mg / 10 mg |
| Primary research focus | Satiety signaling, gastric emptying, body weight regulation |
| Combination of interest | CagriSema (cagrilintide + semaglutide) |
Amylin biology
Native amylin is co-secreted with insulin in approximately a 1:100 molar ratio. Its receptors are heterodimeric complexes of the calcitonin receptor with one of three receptor activity modifying proteins (RAMP1, RAMP2, RAMP3), which together confer amylin selectivity over related calcitonin-family peptides.
In animal research, amylin receptor activation produces three well-characterized effects: suppression of food intake (acting centrally in the area postrema), slowing of gastric emptying, and suppression of postprandial glucagon. These mechanisms are independent of GLP-1 receptor activation, which is why combined amylin + GLP-1 pharmacology has become an active research question.
How cagrilintide differs from native amylin
Native amylin has two practical limitations for research and development: it aggregates into amyloid fibrils, and it has a very short half-life. Pramlintide (an earlier amylin analog) addresses aggregation through residue substitution at positions prone to fibril formation, but its half-life remains short (under an hour in human pharmacokinetic studies).
Cagrilintide retains the anti-aggregation substitutions and adds a lipidated side chain that promotes albumin binding — the same general strategy used in long-acting GLP-1 analogs like semaglutide. The result is a half-life suitable for once-weekly research protocols.
CagriSema: the combination of interest
CagriSema refers to the experimental combination of cagrilintide with semaglutide. The research hypothesis is that combined amylin + GLP-1 receptor agonism produces additive or synergistic effects on satiety, gastric emptying, and body weight endpoints compared with either compound alone — because the two receptor pathways are pharmacologically distinct.
In published animal and early clinical research, the combination has produced larger weight-related effects than GLP-1 monotherapy in matched models. For laboratory research, CagriSema arms are typically constructed by dosing cagrilintide and semaglutide separately rather than as a single co-formulated vial.
How cagrilintide compares to GLP-1 agonists
The two classes are often grouped together in metabolic research literature because they target overlapping endpoints — but they are mechanistically distinct.
- Receptor target: Amylin receptor (calcitonin + RAMP) for cagrilintide; GLP-1 receptor for the GLP-1 class.
- Mechanism of satiety: Both reduce food intake in animal models, but via different central pathways (area postrema for amylin, multiple sites including hypothalamus and brainstem for GLP-1).
- Glucose handling: Cagrilintide primarily acts via suppression of postprandial glucagon and slowed gastric emptying. GLP-1 agonists add glucose-dependent insulin release.
- Use in combination research: The two classes are studied together specifically because they activate non-overlapping pathways with parallel endpoints.
Lab handling at a glance
Lyophilized cagrilintide is stable at −20°C to −80°C for typical research timeframes. Reconstitution follows the same procedure used across long-acting GLP-1 analogs: bacteriostatic water for in vitro work over weeks, gentle swirling rather than shaking to avoid foaming, and storage of the reconstituted vial at 2-8°C with limited freeze-thaw of aliquots.
For a step-by-step protocol that applies to this class, see How to Reconstitute Tirzepatide. The procedure is shared across long-acting incretin and amylin analogs — only the vial-size-specific dilution math differs.
When to choose cagrilintide in a research design
- Investigating amylin receptor pharmacology: cagrilintide is the long-acting reference compound.
- CagriSema arm: required for combined amylin + GLP-1 study designs.
- Comparative satiety mechanism work: cagrilintide pairs naturally with GLP-1 agonist arms for pathway separation.
- Long-acting profile required: use cagrilintide rather than pramlintide where a weekly research cadence is needed.
For Research Use Only. Information presented for laboratory and research applications. Not medical advice and not a substitute for qualified scientific judgment.